Short-interval lower-dose intravenous cyclophosphamide as induction and maintenance therapy for lupus nephritis: A prospective observational study

Clinical Rheumatology

Volumn 33, Issue 7, 2014, Pages 939-945

  Zhang, X W ^a   Li, Chun ^a   Ma, X X ^a   Zhao, J X ^b   An, Yuan ^a   Liu, Shuang ^a   Li, Yan ^a   Li, Z G ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b PEKING UNIVERSITY THIRD HOSPITAL   (China)

Author keywords

Cyclophosphamide; Lupus nephritis; Menstrual disturbance

Indexed keywords

ANTIBIOTIC AGENT; ANTIVIRUS AGENT; CREATININE; CYCLOPHOSPHAMIDE; DOUBLE STRANDED DNA ANTIBODY; PREDNISONE; SERUM ALBUMIN; IMMUNOSUPPRESSIVE AGENT;

ADULT; ALBUMIN BLOOD LEVEL; ANTIBIOTIC THERAPY; ANTIBODY BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; CLINICAL TRIAL; CONVALESCENCE; CREATININE BLOOD LEVEL; DISEASE ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG PULSE THERAPY; DRUG SAFETY; DRUG WITHDRAWAL; END STAGE RENAL DISEASE; EVENING DOSAGE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEMODIALYSIS; HERPES ZOSTER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LEUKOCYTE COUNT; LEUKOPENIA; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MENSTRUAL IRREGULARITY; MENSTRUATION DISORDER; NAUSEA; OBSERVATIONAL STUDY; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN URINE LEVEL; REMISSION; SHORT COURSE THERAPY; SIDE EFFECT; SLEDAI; TOXIC HEPATITIS; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; COMPLICATION; CONTROLLED STUDY; DRUG ADMINISTRATION; DRUG EFFECTS; INTRAVENOUS DRUG ADMINISTRATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MENSTRUAL CYCLE; MIDDLE AGED; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; TIME; TREATMENT OUTCOME;

ADULT; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MENSTRUAL CYCLE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEINURIA; REMISSION INDUCTION; SERUM ALBUMIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84903525870     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-014-2590-6     Document Type: Article

References (28)

1. Cameron JS (1999) Lupus nephritis. J Am Soc Nephrol 10:413-424
2. Donadio JV Jr, Holley KE, Ferguson RH, Ilstrup DM (1978) Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide. N Engl J Med 299:1151-1155 (Pubitemid 9065570)
3. Houssiau FA, Vasconcelos C, D'Cruz D et al (2002) Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 46:2121-2131
4. Mok CC, Ho CT, Chan KW, Lau CS, Wong RW (2002) Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine. Arthritis Rheum 46:1003-1013 (Pubitemid 34303813)
5. Yee CS, Gordon C, Dostal C et al (2004) EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis. Ann Rheum Dis 63:525-529 (Pubitemid 38530195)
6. Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725
7. Balow JE, Boumpas DT, Fessler BJ, Austin HA 3rd (1996) Management of lupus nephritis. Kidney Int Suppl 53:S88-S92 (Pubitemid 26023112)
8. Chan TM, Li FK, Tang CS et al (2000) Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 343:1156-1162
9. Chan TM, Li FK, Wong RW, Wong KL, Chan KW, Cheng IK (1995) Sequential therapy for diffuse proliferative and membranous lupus nephritis: cyclophosphamide and prednisolone followed by azathioprine and prednisolone. Nephron 71:321-327
10. Boumpas DT, Austin HA 3rd, Vaughn EM et al (1992) Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340:741-745
11. Martin-Suarez I, D'Cruz D, Mansoor M, Fernandes AP, Khamashta MA, Hughes GR (1997) Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide. Ann Rheum Dis 56:481-487 (Pubitemid 27396035)
12. Stojanovich L, Stojanovich R, Kostich V, Dzjolich E (2003) Neuropsychiatric lupus favourable response to low dose i.v. cyclophosphamide and prednisolone (pilot study). Lupus 12:3-7 (Pubitemid 36172655)
13. Houssiau FA, Vasconcelos C, D'Cruz D et al (2004) Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum 50:3934-3940 (Pubitemid 39643941)
14. Takada K, Illei GG, Boumpas DT (2001) Cyclophosphamide for the treatment of systemic lupus erythematosus. Lupus 10:154-161 (Pubitemid 32410070)
15. Mok CC, Ho CT, Siu YP et al (2001) Treatment of diffuse proliferative lupus glomerulonephritis: a comparison of two cyclophosphamide-containing regimens. Am J Kidney Dis 38:256-264
16. Dooley MA, Jayne D, Ginzler EM et al (2011) Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 365:1886-1895
17. Pistiner M, Wallace DJ, Nessim S, Metzger AL, Klinenberg JR (1991) Lupus erythematosus in the 1980s: a survey of 570 patients. Semin Arthritis Rheum 21:55-64
18. Lee P, Urowitz MB, Bookman AA et al (1977) Systemic lupus erythematosus. A review of 110 cases with reference to nephritis, the nervous system, infections, aseptic necrosis and prognosis. Q J Med 46:1-32 (Pubitemid 8041047)
19. Wallace DJ, Podell T, Weiner J, Klinenberg JR, Forouzesh S, Dubois EL (1981) Systemic lupus erythematosus - survival patterns. Experience with 609 patients. JAMA 245:934-938 (Pubitemid 11154415)
20. Esdaile JM, Levinton C, Federgreen W, Hayslett JP, Kashgarian M (1989) The clinical and renal biopsy predictors of long-term outcome in lupus nephritis: a study of 87 patients and review of the literature. Q J Med 72:779-833 (Pubitemid 19230673)
21. Gruppo Italiano per lo Studio della Nefrite Lupica (GISNEL) (1992) Lupus nephritis: prognostic factors and probability of maintaining life-supporting renal function 10 years after the diagnosis.
22. Austin HA 3rd, Boumpas DT, Vaughan EM, Balow JE (1994) Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. Kidney Int 45:544-550 (Pubitemid 24065091)
23. Lim CS, Chin HJ, Jung YC et al (1999) Prognostic factors of diffuse proliferative lupus nephritis. Clin Nephrol 52:139-147 (Pubitemid 29419467)
24. Ong LM, Hooi LS, Lim TO et al (2005) Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrol (Carlton) 10:504-510 (Pubitemid 41727277)
25. Katsifis GE, Tzioufas AG (2004) Ovarian failure in systemic lupus erythematosus patients treated with pulsed intravenous cyclophosphamide. Lupus 13:673-678 (Pubitemid 39279782)
26. Huong DL, Amoura Z, Duhaut P et al (2002) Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients. J Rheumatol 29:2571-2576 (Pubitemid 35416964)
27. Harward LE, Mitchell K, Pieper C, Copland S, Criscione-Schreiber LG, Clowse ME (2013) The impact of cyclophosphamide on menstruation and pregnancy in women with rheumatologic disease. Lupus 22:81-86
28. Medeiros MM, Silveira VA, Menezes AP, Carvalho RC (2001) Risk factors for ovarian failure in patients with systemic lupus erythematosus. Braz J Med Biol Res 34:1561-1568 (Pubitemid 34874039)